Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD

This study is examining whether dapagliflozin — a diabetes and kidney protection medication — improves the structure and function of the heart in people with chronic kidney disease (CKD). **You may be eligible if...** - You are 18 or older - You have chronic kidney disease with reduced kidney function (specific eGFR ranges) or with significant protein in your urine - You have been on a stable dose of a blood pressure/kidney-protective medication (ACE inhibitor or ARB) for at least 4 weeks **You may NOT be eligible if...** - You are already taking a medication in the same class as dapagliflozin (SGLT2 inhibitors) - You have type 1 diabetes - You have severe heart failure (certain classifications) - Your kidney function is below the required minimum - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.